CLINICAL SUPPLY PLANNING ARTICLES
Is The BIOSECURE Act The First Real Step Toward Reshoring?
The U.S. pharma industry has relied heavily on China and India to produce regulatory starting materials and APIs. The BIOSECURE Act has now emerged. Is this the first real step toward reshoring?
CLINICAL SUPPLY PLANNING VIDEOS
Examine how data-driven decisions and a reduced burden for sites and participants can help ensure that clinical trial treatments will be delivered on time and in the condition required.
This panel webinar discusses the importance of clinical supply agility and how to mitigate supply chain risk that comes along with clinical supply decisions.
Expert speakers discuss current operational obstacles and explore strategic solutions to optimize a supply chain strategy in the years ahead.
Industry experts share insights to help you mitigate supply chain risk and accelerate access to novel cell and gene therapies.
CLINICAL SUPPLY PLANNING RESOURCES
-
![Vials pharma manufacturing GettyImages-618518692]( "Planning Your Packaging For A Seamless Transition From Clinic To Launch")
Explore how clinical and commercial teams should work together for clinical supply packaging, how the COVID-19 pandemic has changed things, and what to consider when looking for a packaging partner.
-
![iStock-1213895723-cold chain-packaging-logistics-storage]( "Overcoming Cell Therapy Supply Chain Challenges")
For the industry to realize the potential of cell and gene therapies (CGTs), we must develop improved solutions that reliably support the control and transport of critical CGT raw materials and products.
-
![Warehouse Boxes]( "Trade Compliance: Challenges In Global Biopharma Materials Logistics")
Have you noticed that it has become increasingly difficult to transport your material into and out of the United States? That’s because it has!
-
![syrine vials globe]( "Safely Transporting Medicines To Patients")
Do pharma companies underestimate supply chain challenges? Much can go wrong when sending a therapy from A to B, but the right collaborations can mitigate risk.
-
![iStock-1163081129-doctor-clinical-study]( "Q&A: Comparator And Co-Therapy Drug Sourcing For Clinical Studies")
Rachel Curran, Head of Sourcing Services and Special Accounts, discusses the requirements, challenges, and solutions to comparator and co-therapy drug sourcing for clinical trials.
-
![gettyimages-1022854424-170667a]( "Optimizing Resupply To Reduce Risk Of Late Phase Delays")
Early collaboration with a clinical supply manager can help proactively negotiate potential pitfalls. Learn efficient resupply practices and execute successful supply chain strategies.
-
![Cells]( "The RMAT Designation: What It Means To The Advanced Therapy Supply Chain")
The RMAT designation gives the sponsor of a new drug access to increased meeting opportunities with FDA, in a manner comparable to those offered to sponsors of breakthrough-designated therapies. In fact the RMAT may be considered as analogous to the breakthrough designation for regenerative medicine drugs.
